DoD awards Nanotherapeutics contract for MCM ADM Development
The DOD just closed the bidding process for the development of MCM ADM capabilities to protect and treat military personnel against chemical, biological, radiological and nuclear attacks, as well as outbreaks of naturally emerging and man-made diseases. Nanotherapeutics, a privately held biopharmaceutical company, was named the winner.
The goal of the contract is to make the process of developing and manufacturing Food and Drug Administration approved medical countermeasures more efficient. Nanotherapeutics is the prime contractor and will work with industry partners to accomplish this goal.
Nanotherapeutics will use new technologies to support national security requirements for medical countermeasures by creating single-use, disposable equipment. The company has assembled a team to merge new biomanufacturing technologies to existing manufacturing processes for the creation of medical countermeasures. These new advancements will help the DoD respond quickly to CBRN events.
Nanotherapeutics was founded in 1999 with a focus on developing a wide array of products that can be used in both biodefense and medicine. The company uses in-house cGMP manufacturing, formulation and expertise to create its products.